Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘NRG1’

A phoenix rises from the ashesResilience in purpose and openess in strategic direction are key dual features in the DNA of strong biotechs which succeed in the long run and live to survive the roller coaster ride that is oncology R&D.

Setbacks are to be expected, but what matters more is not that they happen, but the mettle and toughness to deal with them over time.

There is no doubt Clovis Oncology encountered a major setback with the abandonment of rociletinib in lung cancer, while the rise of PARP inhibitors meant they were well placed with the rucaparib development.

Beyond these events, what next?

It’s time to take a bigger picture look at what’s happening with the pipeline and where they might be heading since there could be some surprises in store…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to ESMO20 virtual congress, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Boston: The 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics is underway (#Targets19). It’s long been one of our favorite meetings, particularly when held in Boston, and this year there’s a raft of early ideas on offer as to where the targeted therapy field may be going.

Alison Schram, MD. Credit: MSKCC

The success of Ignyta’s entrectinib (acquired by Roche) and Loxo Oncology’s larotrectinib (acquired by Lilly) in targeting NTRK gene fusions has raised interest in targeting other gene fusions, even if they are rare. A new target in a similar vein that has attracted interest recently are fusions involving the neuregulin 1 gene (NRG1).

At this year’s Molecular Targets meeting, Dr Alison Schram, a medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) presented clinical proof of concept data for MCLA-128 (Merus), a bispecific HER2/3 antibody therapy in NRG1 fusion positive cancers.

What did we learn about MCLA-128 and NRG1 at Targets19?

To learn more from our Triple/Targets meeting oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!